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ing cardiovascular mortality, myocardial infarction (MI), or stroke among patients 
with acute coronary syndrome (ACS) compared to clopidogrel but without a signifi-
cant increase in major bleedings. In Hong Kong, generic clopidogrel was introduced 
in 2012. This study aimed to evaluate the long-term cost-effectiveness of ticagrelor 
in ACS patients in Hong Kong (HK) from a public hospital’s perspective. Methods: 
A two-phase Markov model was used to estimate the short- and long-term cost-
effectiveness measured as cost per quality-adjusted-life-year (QALY) and cost per 
life-year-gained (LYG) over 1 year, 5 years and patients’ lifetime. Direct medical costs 
were HK-specific and patients’ resource use, rate of cardiovascular events (i.e. MI 
and stroke) and utility data were from published literature. All costs were presented 
as 2014 figures, cost and effectiveness were both discounted at 3% per annum. 
Sensitivity analyses were performed to test model robustness. Results: Despite 
the great difference in the daily drug cost of ticagrelor and generic clopidogrel 
(US2.8, vs US0.10,1US= 7.8HK), the overall cost of management between the 2 groups 
remains similar. Our study shows that the incremental cost-effectiveness ratios 
(ICER) of ticagrelor were reduced substantially from US16,071/LYG and US19,493/
QALY in the first year to US302/LYG and US357/QALY over a lifetime time horizon 
due to improvements in health outcomes. The ICER values were all cost-effective 
based on the WHO 3xGDP criteria (GDP 2013= US37,860). The results are sensitive 
to cost of generic clopidogrel. ConClusions: Treating ACS patients with lifetime 
use of ticagrelor can potentially reduce the cost of management and increase the 
cost-effectiveness due to better health outcomes as compared to generic clopidogrel. 
Ticagrelor therapy appears to be cost-effective both on short- and long-term assess-
ment in the public health care sector of Hong Kong.
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objeCtives: The purpose of this project was to evaluate the incremental costs of 
increasing physical activity and improving body composition for a lifestyle walking 
program targeting sedentary African American women. Methods: The Women’s 
Lifestyle Physical Activity Program was a randomized behavioral trial that included 
a group intervention with social support and culturally relevant, tailored content 
about increasing physical activity and an automated telephone response system 
to track physical activity for sedentary African American women ages 40-65. The 
principal outcomes were change in minutes of walking and moderate and vigorous 
physical activity per week, and body mass index (BMI) between baseline and 24 
weeks. Incremental cost effectiveness ratios (ICER) were calculated for each out-
come.  The cost-effectiveness analysis included both program and participant costs 
and was calculated in 2013 US dollars. Results: For the 260 participants in the 
analysis, participant costs (e.g., group session attendance, logging physical activity 
in the ATR system) were $152 ± 42, while program costs (e.g., group session facilita-
tion, materials and supplies) were $164 ± 21, for a total cost of $316 ± 59. Walking 
increased by 200 minutes per week at 24 week, with an ICER of $1.64 (95% CI, 1.63 
– 1.66) per minute, moderate and vigorous physical activity increased by 117 min-
utes per week, with an ICER of $2.79 per minute, and BMI decreased by 0.09 points, 
with an ICER of $3463 (95% CI, 500 – 9,540) per 1-point reduction. ConClusions: 
The Women’s Lifestyle Physical Activity Program is a relatively low cost strategy for 
increasing physical activity. The incremental cost of increasing walking minutes 
is substantially lower than for moderate and vigorous physical activity. The par-
ticipant costs related to time in the program were more than half of the total costs, 
suggesting that practitioners and policymakers should consider the participant cost 
when disseminating group programs into practice.
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objeCtives: The study assessed the lifetime cost-effectiveness of apixaban in pre-
venting thromboembolic events in non-valvular atrial fibrillation (NVAF) patients, 
as compared to other novel oral anticoagulant agents (NOACs), from the Italian 
Health System (SSN) perspective. Methods: A previously published Markov 
model was adapted. Baseline clinical risks were assigned based on the demo-
graphic and clinical features of the patients; effectiveness parameters derived 
from adjusted indirect comparison using warfarin as link. Expected survival 
was projected beyond trial duration using national mortality data adjusted for 
clinical risks and weighted by published utilities. Unit costs were collected from 
official and published Italian sources. Costs (2013-€ ) and health gains occurring 
after the first year were discounted at an annual 3.5% rate. Deterministic and 
probabilistic sensitivity analyses (DSA&PSA) were carried out. Results: In the 
short to medium term, apixaban was associated with marginal LYs and QALYs 
gains and slight savings. However, as apixaban extended expected survival ver-
sus dabigatran (110mg), dabigatran (150mg) and rivaroxaban (0.13,0. 08, and 0.06 
LYs or 0.11,0. 07, and 0.05 QALYs), expected total lifetime costs exceeded those of 
these comparators (319,282,16 € ). Corresponding ICERs were estimated in € 2,911, 
€ 3,882 and € 327 per QALY gained. In PSA, the probabilities of apixaban being cost 
effective with a WTP threshold of 20,000 € /QALY gained were 99%, 92% and 93% 
for the same comparisons. The most influential parameter according to DSA was 
daily cost of NOACs, but the corresponding ICERs remained well below commonly 
accepted WTP values. ConClusions: Apixaban is expected to be more effective 
than dabigatran and rivaroxaban in Italian NVAF patients, and marginally more 
costly due to costs in added years of life. The ICERs have a high likelihood of being 
below conventional thresholds of WTP for health benefits of the SSN and suggest 
that apixaban is cost-effective compared with other NOACs.
effectiveness data were derived from head-to-head randomized trials (ARISTOTLE 
and AVERROES); main events considered in the model were ischemic and hemor-
rhagic stroke, systemic thromboembolism, bleeds (both major and clinically rel-
evant minor) and cardiovascular hospitalizations. Expected survival was projected 
beyond trial duration using national mortality data adjusted for individual clinical 
risks and adjusted by utility weights for health states derived from literature. Unit 
costs were collected from published Italian sources. Costs (2013 € ) and health gains 
accruing after the first year were discounted at an annual 3.5% rate. Deterministic 
and probabilistic sensitivity analyses (PSA) were carried out to assess the effect of 
input uncertainty. Results: Incremental LYs (0.31/0.19), QALYs (0.28/0.20), and costs 
(1,932/1,104) are predicted with the use of apixaban relative to aspirin and warfarin, 
respectively. The incremental cost effectiveness ratios (ICERs) of apixaban were € 
6,794 and € 5,607 per QALY gained, respectively. In PSA, the probability of apixaban 
being cost effective relative to aspirin and warfarin was 95% and 93%, respectively, 
for a WTP threshold of € 20,000 per QALY gained. Univariate analyses indicate that 
results were most sensitive to variations of the absolute risk reduction for cardiovas-
cular events with apixaban. ConClusions: Apixaban is expected to increase life 
expectancy and quality-adjusted life expectancy, but also costs dedicated to Italian 
NVAF patients, as compared to standard of care. The resulting ICERs have high prob-
abilities of being below the conventional thresholds of WTP for health benefits of 
the SSN, indicating efficient allocation of health care resources.
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objeCtives: Systematic anticoagulation management clinic is now recom-
mended to manage warfarinized atrial fibrillation (AF) patient. In Malaysia, the 
service is recently introduced as pharmacist managed Warfarin Medication Therapy 
Adherence Clinic (WMTAC). The objective of the present study was to assess the 
cost effectiveness of anticoagulation clinic in comparison with usual medical 
in Kuala Lumpur Hospital. Methods: A Markov model built using the provider 
perspective and 20 year time horizon was used to assess the cost effectiveness. 
The base case analysis assumed a cohort of patients with AF 57 years of age with 
comorbid illnesses. Data sources include a 6 month retrospective cohort analysis 
of the effectiveness of the clinics, the cost of drugs, cost of personnel and space 
of the clinics, cost of monitoring and cost of adverse events were obtained from 
the local source and publications. The transition probabilities of these clinics out-
comes were obtained from a literature search. Future costs were discounted by 
3% to convert to present values. All costs were in Ringgit Malaysia (RM) based on 
year 2012. Results: The results of a 20-year period model showed that UMC was 
dominated by the WMTAC in the same time period. The mean cost of the WMTAC 
was RM 5864 whereas the UMC cost was RM 6550. The sensitivity analysis showed 
that clinic treatment costs and effectiveness influenced the cost-effectiveness. If the 
cost of WMTAC was increased by 50% of the current cost, the WMTAC would not be 
a dominant intervention. WMTAC was also cost effective for a willingness to pay of 
RM32000. ConClusions: The anticoagulation management service appears to cost 
less and provide greater effectiveness than usual care. In conclusion, the Markov 
model suggests that from the provider perspective the anticoagulation clinic is a 
more cost effective option than the usual medical clinic in Kuala Lumpur Hospital.
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objeCtives: To assess cost-effectiveness of ranolazine in Russian patients with 
angina pectoris. Methods: A model was developed to compare a strategy of treat-
ment of angina pectoris with ranolazine and a traditional therapy in patients with 
at least 3 heart attacks per week. The analysis was based on the results of ERICA 
(Efficacy of Ranolazine in Chronic Angina) study that included Russian patients and 
reflected a routine Russian practice for the treatment of the disease. The analysis 
included costs of drug therapy, emergency care and hospitalization. Effectiveness 
rate was measured as a change of frequency of angina attacks compared to initial 
level estimated by SAQ (Seattle Angina Questionnaire). Sensitivity analysis con-
sidered the change of parameters in different length of hospitalization. Results: 
Total costs in ranolazine group were insignificanlty higher than in control group 
(573.84 RUB per patient). At the same time, ranolazine changed the structure of 
costs: expenditures on medications grew while costs of emergency care and hos-
pitalization reduced. CER value was 1640.86 in ranolazine group, and 1964.63 (1.2 
times less) in group of traditional therapy. The change of hospitalization length in 
sensitivity analysis was also more favorable in case of ranolazine: 164 479.81 vs 
197 300.02 RUB/unit, which confirms previous results. ConClusions: The use of 
ranolazine in patients with > 3 heart attacks of angina pectoris per week is clinically 
and economically substantiated.
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objeCtives: The multi-centered, double-blind, randomized PLATO trial on 18,624 
patients from 43 countries has demonstrated that ticagrelor was superior in reduc-
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reached CZK885,044 (~EUR32,260), with the Cardiohelp device (Maquet, Germany) 
CZK788,432 (~EUR28,738). The cost utility analysis revealed 3,961,970 CZK/QALY 
(~144,413 EUR/QALY) with Cardiohelp, and 4,447,457 CZK/QALY (~162,109 EUR/
QALY) when using Levitronix Centrimag. However, if only patients with CPC 1 were 
included into the analysis, the cost-utility ratio decreased to 834,616 CZK/QALY 
(~30,422 EUR/QALY) and 908,253 CZK/QALY (~33,106 EUR/QALY) for Cardiohelp and 
Levitronix, respectively. ConClusions: Our data indicate that ECPR for refractory 
cardiac arrest might be cost effective despite the high costs per individual patient 
treated with this approach. Larger studies are, however, required to confirm these 
observations.
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objeCtives: Raised heart rate is a risk factor for cardiovascular events and 
death. Heart rate reduction could be an important role in management of chronic 
heart failure. Ivabradine is a new, pure and specific heart rate lower therapy. We 
assessed the cost effectiveness of Ivabradine in CHF with heart rate 75 bpm 
using the perspective of a middle-income country’s public health insurance sys-
tem. Methods: Model-based analysis closely mirrored the SHIFT trial was per-
formed. Micro-simulation method of CHF disease, mortality and hospitalization 
were used to compare Ivabradine plus standard care with standard care only. 
A two state Markov model has been employed to simulate the natural history of 
disease. Costs were estimated from national health insurance research database 
in Taiwan, a single-payer program that offers universal health care coverage. And 
another estimated costs using a medical center in Taiwan with clinical examina-
tion value were performed to validate the accuracy of costs. Incremental cost per 
quality adjusted life year (QALY) gained is used to express the value of Ivabradine 
over a lifetime horizon and 29 months of trial period. Results: The incremen-
tal cost per additional QALY for Ivabradine plus standard care versus standard 
care has been estimated as £14,832 for trial period and £7,634 for lifetime. 
Ivabradine is cost-effective according to NICE threshold. And the result was 
robust in sensitivity analysis. ConClusions: In a middle-income country like 
Taiwan, the use of Ivabradine to treat the eligible CHF patients is likely to be cost 
effectiveness.
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objeCtives: To conduct an economic analysis of the risk assessment of venous 
thromboembolism (VTE) from the perspective of the Spanish National Health 
System with Thrombo inCode versus conventional/standard method used to date 
(Factor V Leiden and Prothrombin G20210A). Methods: An economic model 
was created from the National Health System perspective using a decision tree 
in patients aged 45 with a life expectancy of 81 years. The predictive capacity of 
VTE based on the identification of thrombophilia with Thrombo inCode and of the 
standard method was obtained from two case-control studies (S. PAU and MARTHA) 
conducted on two different populations (1,451 patients in all). Although this is not 
always the case, in this analysis the least favourable situation was assumed for 
Thrombo inCode, with patients identified as suffering from thrombophilia being 
subject to preventive treatment of VTE with warfarin, leading to a reduction in 
the number of VTE events and an increased risk of severe bleeding. The health 
states utilities (quality-adjusted life years, QALY) and costs were obtained from 
the literature and Spanish sources. Results: Based on a price of € 180 for Thrombo 
inCode, this would be the dominant option (more effective and with lower costs than 
the standard method) in both populations. The Monte Carlo probabilistic analyses 
indicate that the dominance would occur in 100% of the simulations in both popu-
lations. The threshold price of Thrombo inCode needed to reach the incremental 
cost-effective ratio (ICER) generally accepted in Spain (€ 30,000 per QALY gained) 
would be between € 3,950 (MARTHA) and € 11,993 (S. PAU). ConClusions: Thrombo 
inCode is a dominant option in assessing the risk of VTE compared to the standard 
method currently used.
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objeCtives: Treatment of varicose veins (VV) has been shown to increase health 
related quality of life. However, the cost-effectiveness of such treatments has been 
uncertain. Indeed there is great regional variation across the UK in how, and if, VV 
are treated. This economic analysis formed part of the NICE clinical guideline on VV, 
with an objective to investigate whether such treatments should be recommended 
across the UK. Methods: An economic analysis was conducted to compare the 
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objeCtives: Non-invasive molecular imaging tests are currently being developed 
to improve individual stroke risk prediction in patients with a recent transient 
ischemic attack (TIA) or minor ischemic stroke. We estimated the minimum per-
formance (i.e., sensitivity and specificity) that a test must have in order to be more 
cost-effective than current clinical practice. Methods: The aim of imaging tests is 
to identify which patients should undergo surgery instead of receiving medicines. 
Decision modelling was used to estimate the minimum performance of a confirma-
tory test that is performed based on the result of an initial duplex ultrasonography. 
The comparators were patient management according to Dutch guidelines and three 
observed clinical practice strategies. Scenario analyses were performed in which the 
sensitivity and specificity were varied to estimate the minimum test performance 
needed to be cost-effective versus the comparators. Results: A perfect confirma-
tory test (100% sensitivity and specificity) with a cost of € 390 for a 60-year-old man 
is cost-effective versus all comparators. Assuming 100% sensitivity, a test must be at 
least 71% specific to be cost-effective versus the Dutch guidelines using a threshold 
of € 30,000/QALY. Similarly, assuming 100% specificity, a test must be at least 52% 
sensitive to be cost-effective. In addition, assuming 90% sensitivity, a test must have 
a specificity of at least 77% to be cost-effective. Moreover, the minimum values of 
sensitivity and specificity needed for a test to be cost-effective are dependent on the 
QALY threshold used. ConClusions: An imaging test that improves risk prediction 
and therefore treatment decisions for patients with a recent TIA or minor ischemic 
stroke has the potential to improve cost-effectiveness by reducing the risk of recur-
rent stroke. However, developers must consider if the minimum test performance 
required to be cost-effective can be achieved; other concerns of payers (e.g. budget 
impact) must also be considered.
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objeCtives: Guidelines suggest only 3-6 months of anticoagulant treatment in 
most venous thromboembolism (VTE) patients due to concerns that the bleeding 
risk with vitamin K antagonists (VKAs) outweighs the reduced risk of VTE recur-
rence in extended treatment. However, non-VKA novel oral anticoagulants (NOACs) 
have been studied recently for extended VTE treatment. Apixaban demonstrated 
superiority to placebo in VTE reduction without increasing risk of major bleeding in 
the AMPLIFY-EXT trial, justifying reassessment of the potential benefit of extending 
treatment. This analysis reports cost effectiveness of lifetime treatment with apixa-
ban versus rivaroxaban, dabigatran, and low-molecular-weight heparin (LMWH)/
KA from the perspective of the UK National Health Service (NHS). Methods: 
A Markov model was developed that includes the following health states: recurrent 
VTE, major bleed, clinically-relevant non-major bleed, chronic thromboembolic 
pulmonary hypertension, and death. Transition rates among health states were 
based upon AMPLIFY and AMPLIFY-EXT clinical trial data, network meta-analyses, 
discontinuation due to clinical events, and UK life tables. Costs were from UK NHS 
Healthcare Resource Group tables and utilities were from published literature. The 
primary outcome of interest was incremental cost per quality adjusted life year 
(QALY) gained. Results: Compared to other anticoagulants, lifetime treatment 
with apixaban was projected to result in fewer bleeds and fewer recurrent VTEs. 
The lower bleeding risk with apixaban led to fewer treatment discontinuations, 
longer time on treatment, and fewer recurrent VTEs. The reduced number of clini-
cal events led to increased QALYs at a nominal cost increase, due primarily to 
longer treatment duration with apixaban. Incremental costs per QALY gained 
were £2,781, £619, and £10,820 for apixaban versus dabigatran, rivaroxaban, and 
LMWH/VKA, respectively. Sensitivity analyses indicated that results were robust 
to a wide range of inputs. ConClusions: Apixaban for lifetime treatment of VTE 
can offer substantial clinical benefits and is a cost-effective alternative to other 
NOACs and LMWH/VKA.
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objeCtives: Extracorporeal life support (ECLS) has been recently introduced as a 
therapeutic option for refractory cardiac arrest (extracorporeal cardiopulmonary 
resuscitation - ECPR). Despite growing evidence demonstrating improved sur-
vival rate with ECPR in refractory cardiac arrest, a number of questions remains 
unanswered and data on cost-effectiveness of this approach are still insuffi-
cient. Methods: Retrospective cost-effectiveness analysis was performed from 
the provider’s perspective. Sixteen patients undergoing ECPR were included into 
the analysis (ECPR group) and the data were compared with 35 subjects with con-
ventional CPR for refractory cardiac arrest (non-ECPR group). Results: In the 
ECPR group seven out of sixteen patients were weaned from ECMO, four of them 
with good neurological outcomes (CPC 1); three patients survived one year with 
CPC 1, one patient survived one year with severe neurological dysfunction (CPC 
3) and one patient with persisting coma (CPC 4). In comparison, in the non-ECPR 
group all patients died within 24 hours. In the ECPR group, when using Levitronix 
Centrimag blood pump (Thoratec, USA), the average annual costs per patient 
